The FDA’s nod for suzetrigine bolsters confidence in the pharmaceutical industry’s strategy to target sodium channels.

Platinum-based or taxane chemotherapy drugs appear to pose the greatest risk for nerve pain, and lung cancer patients seem to have the highest rates of neuropathy, results show. Related 2 dead ...